Want to see PBLS full AI Analyst Report?
PBLS Stock Chart & Stats
$35.58
-$0.58(-1.63%)
At close: 4:00 PM EDT
$35.58
-$0.58(-1.63%)
Day’s Range― - ―
52-Week Range$24.51 - $41.49
Previous Close$33.5
Volume69.93K
Average Volume (3M)N/A
Market Cap
$4.86B
Enterprise Value$2.31K
Total Cash (Recent Filing)$1.12B
Total Debt (Recent Filing)$47.51M
Price to Earnings (P/E)―
Beta-0.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding121,952,030
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.67Price Target Upside14.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline AdvancementProgressing zolucatetide toward registrational development could create a path to future commercialization and diversify the company beyond discovery-stage research if clinical and regulatory milestones are achieved.
Strategic Research CollaborationThe Regeneron collaboration validates the potential of the Helicon platform and may expand development capacity, scientific reach, and future partnering opportunities across antibody-drug conjugate programs.
Debt ReductionLower debt provides a modest offset to broader balance-sheet weakness by reducing absolute obligations, although the benefit is limited because continuing cash burn may require additional external financing.
Bears Say
Minimal Commercial RevenueThe absence of a meaningful revenue base leaves the company dependent on clinical progress and capital markets rather than operating sales, increasing execution risk before any product commercialization.
Widening Losses And Cash BurnWidening losses and accelerating operating cash outflows indicate that development activities are consuming substantial capital, which can increase financing needs and potential shareholder dilution over the coming periods.
Negative Equity And Balance-sheet StrainThe move to negative equity and sharp asset decline signal accumulated losses and reduced financial flexibility, potentially limiting borrowing capacity and making continued reliance on external funding more consequential.
Parabilis Medicines, Inc. News
PBLS FAQ
What was Parabilis Medicines, Inc.’s price range in the past 12 months?
Parabilis Medicines, Inc. lowest stock price was $24.51 and its highest was $41.49 in the past 12 months.
What is Parabilis Medicines, Inc.’s market cap?
Parabilis Medicines, Inc.’s market cap is $4.86B.
When is Parabilis Medicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Parabilis Medicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Parabilis Medicines, Inc. overvalued?
According to Wall Street analysts Parabilis Medicines, Inc.’s price is currently Undervalued.
Does Parabilis Medicines, Inc. pay dividends?
Parabilis Medicines, Inc. does not currently pay dividends.
What is Parabilis Medicines, Inc.’s EPS estimate?
Parabilis Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Parabilis Medicines, Inc. have?
Parabilis Medicines, Inc. has 121,952,030 shares outstanding.
What happened to Parabilis Medicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Parabilis Medicines, Inc.?
Currently, no hedge funds are holding shares in PBLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Parabilis Medicines, Inc. Stock Smart Score
Company Description
Parabilis Medicines, Inc.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
PBLS Stock 12 Month Forecast
Average Price Target
$40.67
▲(14.30% Upside)
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Meiragtx Holdings
―
Kodiak Sciences
―
Tarsus Pharmaceuticals
―
Ownership Overview
26.02% Insiders
65.09% Other Institutional Investors
6.88% Public Companies and
Individual Investors